Caremo Ranked Among "2025 Top 20 Pharmaceutical Formulation CROs in China "

August 1, 2025 – The opening ceremony of the 7th CMC-CHINA Expo concluded successfully this morning.

During the ceremony, the *2025 China Pharmaceutical Industry TOP 101* report and ten core industry chain rankings, jointly initiated by CMC-CHINA Expo and Pharnex, were officially released. Caremo was honored to be named in the 2025 Top 20 Pharmaceutical Formulation CROs in China, one of the ten core rankings, recognizing its technical expertise in the field.

The 2025 Top 20 Pharmaceutical Formulation CROs in China list was rigorously compiled by the industry information platform "Pharnex" through in-depth research and expert evaluation. Selection criteria included core business revenue, comprehensive corporate strength, and industry influence.

This accolade signifies authoritative recognition of Caremo’s technical capabilities and service excellence in pharmaceutical formulation development. It further validates the team’s commitment to continuous innovation and pursuit of excellence.

Caremo specializes in providing comprehensive, high-efficiency formulation development services for both small-molecule generics and innovative drugs. Thanks to sustained investment in CMC capabilities, the company has established multiple complex formulation technology platforms and secured accreditation for two Nanjing Municipal Engineering Research Centers. From R&D to commercialization, Caremo offers global pharmaceutical partners one-stop CMC development services aligned with international standards, accelerating timelines and overcoming development challenges to enable rapid market entry.

Moving forward, Caremo will continue advancing formulation technologies, optimizing service quality and workflows to deliver superior solutions, and contributing to the growth of China’s pharmaceutical industry.